936558-10-0

Upstream product

• 367-21-5 3-chloro-4-fluorophenylamine 
• 165107-97-1 N-(2-cyano-5-fluorophenyl)acetamide 
• 26690-80-2 2-(N-tert-butoxycarbonylamino)ethanol 
• 162012-67-1 N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine 
• 80517-22-2 2-amino-4-fluorobenzonitrile 
• 162012-69-3 7-fluoro-6-nitro-4-hydroxyquinazoline 

Downstream Products

• 936558-11-1 7-(2-aminoethoxy)-N-(3-chloro-4-fluorophenyl)-6-nitro-4-quinazolinamine 

Relevant academic research and scientific papers

EGFR-targeting fluorescence quenching probe and preparation method and application thereof

The invention relates to the technical field of molecular probes, and discloses an EGFR-targeting fluorescence quenching probe and a preparation method and application thereof. The fluorescence quenching probe structurally comprises a pharmacodynamic skeleton structure, a fluorescence quenching group and a fluorescence labeling group, wherein the fluorescence labeling group is selected from BODIPYFL dye; and the fluorescence quenching group is selected from 2, 4-dinitrophenol. The pharmacodynamic skeleton structure can be combined with EGFR protein in a targeting mode, and when the quenchinggroup in the molecular probe leaves, the fluorescence labeling group can conduct specific tracing and imaging; and by means of molecular imaging, the expression process of specific cells and moleculescan be observed in real time, a target spot is traced, and therefore disease development status evaluation and accurate detection of EGFR mutation typing of lung cancer patients are achieved at the molecular pathological level.

QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF

Disclosed are a quinazoline derivative, a preparation method therefor, and a pharmaceutical composition and an application thereof. The present invention provides a compound represented by general formula I, a stereoisomer thereof and a pharmaceutical acceptable salt or a solvate thereof. The quinazoline derivative of the present invention has a unique chemical structure, is characterized by irreversibly inhibiting EGFR tyrosine kinase, has high biological activity, apparently improves the inhibiting effect on the EGFR tyrosine kinase, has quite strong tumor inhibiting effect on tumor cells and a transplantation tumor pathological model of animal tumors, and has good market developing prospects.

QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF

The present invention relates to a novel quinazoline derivative and a pharmaceutically acceptable salt thereof as a multiplex inhibitor, a method for the preparation thereof, and a pharmaceutical composition and a therapeutic composition comprising same as an active ingredient. The inventive quinazoline derivative as a multiplex inhibitor can selectively and effectively inhibit diseases caused by the overactivity of a tyrosine kinase.